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Abstract a-Synuclein is involved in many impor-
tant molecular processes in neuronal cells and their
synapses, and its malfunction has been linked to the
development of Parkinson’s and certain other neu-
rodegenerative diseases. Animal models allowing
tightly monitored conditional inactivation of the
encoding gene, Snca, are indispensible for studies
aimed at understanding normal function of a-synu-
clein in various neuronal populations and its role in
pathogenesis of neurodegenerative diseases. We have
recently reported the production of several novel
mouse lines for manipulating expression of the
endogenous Snca gene, including a line for Cre-
recombinase-driven conditional inactivation of the
gene (mice with floxed Snca) and a new line with a
constitutive knockout of a-synuclein. Rosa26-stop-
lacZ reporter cassette is commonly used for
monitoring efficiency of Cre-recombination but in
mouse genome Snca and Rosa26 loci are located on
the same chromosome. Here we describe production
of lines with a modified Snca locus, either floxed or
constitutively inactivated and the Rosa26-stop-lacZ
reporter cassette located in cis on the mouse chromo-
some 6. These new mouse lines are invaluable for fast
identification of cells with inactivation of Snca by Cre-
recombination and represent useful tools for in vivo
studies of a-synuclein function and dysfunction.
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Introduction
Several missense mutations altering physico-chemical
properties ofa-synuclein as well as increased production
ofa-synuclein caused by duplications and triplications of
the genomic region containing encoding gene, SNCA,
have been associated with the development of familial
forms of Parkinson’s disease (PD) and related disorders
(Polymeropoulos et al. 1997; Kruger et al. 1998;
Singleton et al. 2003; Zarranz et al. 2004; Chartier-
Harlin et al. 2004; Ibanez et al. 2004; Proukakis et al.
2013; Appel-Cresswell et al. 2013; Kiely et al. 2013;
Lesage et al. 2013). Moreover, Lewy bodies and Lewy
neurites, histopathological hallmarks of both hereditary
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and idiopathic forms of PD, are built on a scaffold of
aggregated and fibrillated a-synuclein (Spillantini et al.
1997, 1998). Genome-wide associated and case–control
studies also linkeda-synuclein to idiopathic and familial
forms of PD as well as other synucleinopathies (Kay
et al. 2008; Mizuta et al. 2008; Pankratz et al. 2009;
Scholz et al. 2009; Sutherland et al. 2009).
It is still not clear how altered a-synuclein
metabolism triggers the development of pathological
changes in these neurodegenerative diseases. The gain-
of-function hypothesis is based on multiple evidence of
the toxicity of intermediate products of a-synuclein
aggregation, oligomers and protofibrils. However, a-
synuclein is important for structural and functional
integrity of vertebrate neurons and/or their synapses
(reviewed in Venda et al. 2010) and pathological
aggregation of this protein might cause significant
depletion of its functional pool in neurons and partic-
ularly in presynaptic terminals. Therefore, a contribu-
tion of a-synuclein loss-of-function mechanism to
molecular pathogenesis of synucleinopathies cannot
be discounted, despite no obvious signs of neurode-
generation have been observed in studies of constitu-
tive a-synuclein knockout mice [reviewed in Buchman
and Ninkina (2008)]. These discouraging results can be
explained by efficient mechanisms compensating to
the loss of a-synuclein. It has been suggested that this
compensation takes place in the developing nervous
system during a period of its high plasticity (Al-Wandi
et al. 2010). Depletion of a-synuclein in adult or ageing
nervous system might be significantly more deleteri-
ous. To test this hypothesis an experimental system
allowing conditional inactivation of a-synuclein
encoding gene is required. Moreover, such system
would be invaluable for assessing a-synuclein function
in specific neuronal populations as well as in studies of
a-synuclein aggregation pathology propagation
through the nervous system.
Conditional gene knockout in mice requires a core
mouse line with the gene of interest or its fragment
surrounded by recognition sites for certain specific
recombinases, most commonly Cre or FRT, and a
transgenic mouse line expressing this recombinase in
the particular type of cells. It is important to monitor
the efficiency and specificity of recombination and to
achieve this a reporter gene whose activation by a
recombination event driven by the same enzyme can
be easily detected, is also introduced in the animal
genome. For monitoring Cre-loxP recombination a
Rosa26-stop-lacZ reporter cassette is widely used.
This reporter is usually delivered by another mouse
line carrying a loxP-flanked transcription STOP
sequence, which prevents expression of the down-
stream bacterial lacZ gene encoding b-galactosidase
(Soriano 1999). Activation of Cre-recombinase in a
cell carrying both the reporter and the floxed gene of
interest leads to simultaneous deletion of both floxed
genomic fragments leading to inactivation of the
studied gene and activation of lacZ expression, the
latter can be readily detected due to accumulation of a
colored product of b-galactosidase activity in cells
when specific substrates are added to tissue samples.
We intended to use the Rosa26-stop-lacZ reporter
to monitor conditional inactivation of a-synuclein
coding gene (Snca) in mice carrying this gene with
loxP-flanked first coding exon [Sncaflox] (Ninkina et al.
2015) and tamoxifen-activated Cre-recombinase (Cre/
ERT2) under control of various neuron-specific pro-
moters but this was obscured by co-localisation of
Snca and ROSA26 loci on the same mouse chromo-
some 6. To overcome this obstacle we have previously
produced and used a mouse line with Rosa26-stop-
lacZ cassette and permanently inactivated Snca gene
(Abeliovich et al. 2000) located on the same chromo-
some in cis. Here we describe a similar line but with a
version of permanent Snca gene knockout that lack
problems associated with the presence of Neo cassette
in the genome of mice produced by Abeliovich et al.
(2000), for example dramatic overexpression of
Mmrn1 gene (Ninkina et al. 2015). We also produced
a mouse line that carries Sncaflox gene and Rosa26-
stop-lacZ reporter cassette located in cis at the mouse
chromosome 6. These lines represent useful tools for
production of large cohorts of experimental animals
for conditional inactivation of a-synuclein function.
Materials and methods
Animals
All animals were on C57Bl6J genetic background.
Animal work was carried out in accordance with the
United Kingdom (Scientific Procedures) Act (1986)
and European Directive EC 86/609, and has been
approved by the Cardiff University Ethical Review
Committee and the Home Office (Project Licence
30/2844). The core mouse line for conditional
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inactivation of Snca gene, [Sncaflox_Rosa26wt/
Snca?_Rosa26wt], has been deposited to and now
available from The Jackson Laboratory (C57BL/6-
Snca\tm1.1Vlb[/J; JAX Stock#025636).
Genotyping
Genomic DNA was isolated from mouse ear biopsies
as described elsewhere (Ninkina et al. 2009). PCR
amplification was employed to verify genotypes.
For Rosa26 locus combination of three primers in the
reaction (50-CTTGTGATCCGCCTCGGAGT-30; 50-GG
CATTCATGGGAGTGGAAA-30; 50-TACTGGCCTGC
TCCCTTATC-30) produced 577 and 450 bp amplifica-
tion fragments corresponding to wild type and modified
alleles, respectively.




fragments of 354 bp for Snca?, 280 bp for Snca- and
406 bp for Sncaflox alleles, respectively.
For both amplification reactions 94 C for 2 min
followed by 45 cycles of 94 C for 15 s, 60 C for 20 s
and 72 C for 30 s were used.
Western blot analysis
Total protein extraction from mouse neuronal tissues, SDS-
PAGE separation, semi-dry transfer, blocking, incubation
with antibodies, washing and detection using enhanced
chemiluminescence were carried out as described previ-
ously (Anwar et al. 2011). Antibodies against a-synuclein
(mouse monoclonal, clone 42, BD Transduction Labora-
tories,diluted1:500)andb-actin (mousemonoclonal, clone
AC-15, Sigma diluted 1:5000) were used.
Detection of b-galactosidase activity in brain slices
[Sncaflox_Rosa26mod/Sncaflox_Rosa26mod] mice were
crossed with transgenic mice expressing Cre-ERT2
under control of neurospecific NSE promoter (ob-
tained from Jean C. Manson, The Roslin Institute,
University of Edinburgh) and at the age of 3 month
resulting F1 animals were injected intraperitoneally
with tamoxifen (Sigma-Aldrich) dissolved in corn oil
for five consecutive days (daily dose 75 mg/kg). One
month after activation of Cre recombination by
tamoxifen brains were dissected and transverse slices
(*1 mm thick) through the brainstem were processed
and stained for b-galactosidase activity using X-gal as
a substrate as described elsewhere (Burn 2012).
Results and discussion
Within our previous breeding programme a mouse
founder has been obtained that carried a permanently
inactivated Snca locus from mice originally produced
by Abeliovich et al. (2000) and Rosa26-stop-lacZ
cassette (Soriano 1999) on the same chromosome 6 in
cis. As the physical distance between Snca and Rosa26
loci is 52.3 Mb, which constitutes more than one-third
of total 150 Mb length of mouse chromosome 6
(Fig. 1), and genetic distance is 23.5 cM, high meiotic
recombination frequency between these loci is
expected. Therefore we decided to carry out additional
breeding programme aimed for obtaining mouse lines
carrying other genetic modifications of Snca gene in
cis with Rosa26-stop-lacZ reporter cassette.
The deletion of the Snca exon 2 (first coding exon)
by Cre-loxP recombination in the germline causes
complete arrest of a-synuclein production in homozy-
gous Snca-/Snca- mice. This genomic modification
does not affect expression of neighboring genes, e.g.
Mmrn1 (Ninkina et al. 2015), which is a drawback for
the knockout mice produced by Abeliovich et al. Mice
homozygous for this Cre-induced deletion, [Snca-_-
Rosa26wt/Snca-_Rosa26wt], were crossed with
homozygous mice bearing Rosa26-stop-lacZ cassette,
[Snca?_Rosa26mod/Snca?_Rosa26mod], and resulting
F1 offsprings of [Snca?_Rosa26mod/Snca-_Rosa26wt]
Fig. 1 Relative positions of Snca and Rosa26 loci on mouse chromosome 6
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Fig. 2 A sheme of the breeding protocol that produced mouse
founders carrying a constituent knock-out of a-synuclein-
encoding gene  (exon-2) and Rosa26-stop-lacZ cassette located in
cis on mouse chromosome 6 as the result of meiotic
recombination (a). PCR amplification approach used for
identification of modifications in Snca (b) and Rosa26 (c) loci.
Position of primers within these loci and analysis of corre-
sponding amplification products in agarose gel are shown
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genotype were intercrossed (Fig. 2a). F2 offsprings
were genotyped for both loci (Fig. 2b, c). Between 26
analysed animals one displayed genotype [Snca-_-
Rosa26mod/Snca-_Rosa26wt] (shown in red in
Fig. 2a), which was not consistent with classical
Mendelian inheritance that predicts segregation of
chromosomes and independent assortment of alleles.
Most probably this genotype appeared as a result of a
reciprocal recombination between chromosome 6
bearing Rosa26-stop-lacZ cassette and chromosome
6 bearing Snca null mutant gene during meiosis I
phase of gametogenesis leading to non-Mendelian
segregation of traits. Consequently, a male mouse that
became a founder of a new line carried a chromosome
6 with both Snca- and Rosa26mod loci in cis. Further
backcrossing and intercrossing produced a line of
homozygous [Snca-_Rosa26mod/Snca-_Rosa26mod]
mice.
These homozygous mice were further crossed with
homozygous mice of the core line for conditional
inactivation of a-synuclein-encoding gene, [Sncaflox/
Sncaflox], that have the second exon of Snca gene
flanked with loxP sites in direct orientation. F1
offspring heterozygous for both Snca and Rosa26
loci, [Snca-_Rosa26mod/Sncaflox_Rosa26wt], were
crossed again with homozygous [Snca-_Rosa26mod/
Snca-_Rosa26mod], the Rosa26 genotype of the off-
spring was analysed and animals carrying Rosa26-
stop-lacZ cassette on both chromosomes were selected
for further analysis. Snca genotypes were assessed for
130 of these F2 mice and although majority of animals
displayed either of two expected Mendelian geno-
types, a [Snca-_Rosa26mod/Sncaflox_Rosa26mod]
genotype (shown in red in Fig. 3), was revealed in
11 animals.
Meiotic recombination frequency between these
two loci seems higher during oogenesis than during
spermatogenesis as crosses that involved female F1
[Snca-_Rosa26mod/Sncaflox_Rosa26wt] parent pro-
duces 7 F2 [Snca-_Rosa26mod/Sncaflox_Rosa26mod]
animals from total 64 homozygous Rosa26mod ani-
mals, whereas for crosses that involved male F1
[Snca-_Rosa26mod/Sncaflox_Rosa26wt] parent these
numbers were 4 from 67. Although these results are
not statistically significant with the number of animals
assessed (p[ 0.05, Chi-square test) it might still be
taken into consideration when experimental cohorts
are generated using a breeding programme with
meiotic recombination between these loci is possible
but not desired.
Male and female [Snca-_Rosa26mod/Sncaflox_-
Rosa26mod] founders were intercrossed to produce
Fig. 3 A sheme of the breeding protocol that produced mouse founders carrying floxed exon 2 of a-synuclein-encoding gene (  exon-2 )SNCA
and Rosa26-stop-lacZ cassette located in cis on mouse chromosome 6 as the result of meiotic recombination
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homozygous [Sncaflox_Rosa26mod/Sncaflox_-
Rosa26mod] animals that were further used for estab-
lish a new mouse line.
In this mouse line expression of a-synuclein in
neuronal tissues was the same as in wild type,
[Snca?_Rosa26wt/Snca?_Rosa26wt], animals,
whereas no a-synuclein was detected in neuronal
tissues of the new knockout, [Snca-_Rosa26mod/
Snca-_Rosa26mod], mice (Fig. 4a). As expected, acti-
vation of Cre-recombinase in neurons of [Sncaflox_-
Rosa26mod/Sncaflox_Rosa26mod] mice led to expression
of lacZ gene from the modifiedRosa26 locus (Fig. 4b).
Two new transgenic mouse lines produced in this
study complement a set of previously described mouse
lines (Ninkina et al. 2015) for manipulating endoge-
nous a-synuclein expression and makes generation of
experimental cohorts for experiments required condi-
tional inactivation of a-synuclein function relatively
easy and straightforward.
For example, it is sufficient to obtain mice carrying
a copy of relevant Cre-recombinase along with a copy
of Sncaflox allele, i.e. [Sncaflox_Rosa26wt/Snca?_-
Rosa26wt], and cross them with [Sncaflox_Rosa26mod/
Sncaflox_Rosa26mod] mice to obtain experimental
cohorts, i.e. Cre-positive [Sncaflox_Rosa26mod/
Sncaflox_Rosa26wt] mice, and various control cohorts,
i.e. Cre-positive [Sncaflox_Rosa26mod/Snca?_-
Rosa26wt] mice that will retain one functional copy
of Snca gene even after Cre-recombination takes
place, and Cre-negative mice either homozygous or
heterozygous for Snca gene. Alternatively, Cre-posi-
tive [Sncaflox_Rosa26wt/Snca?_Rosa26wt] mice may
be crossed with another line described here, [Snca-_-
Rosa26mod/Snca-_Rosa26mod] mice, to obtain Cre-
positive heterozygous Snca experimental, [Sncaflox_-
Rosa26wt/Snca-_Rosa26mod] and Cre-positive
heterozygous Snca control, [Snca?_Rosa26wt/
Snca-_Rosa26mod] mice.
Moreover, the [Sncaflox_Rosa26mod/Sncaflox_-
Rosa26mod] line is an obvious choice for experiments
with non-genetic delivery of Cre-recombinase for
local inactivation of Snca gene, e.g. stereotaxic
injection of recombinant viruses expressing this
enzyme, or for preparing primary neuronal cultures
and consequent inactivation of Snca gene by transfec-
tion or viral transduction of Cre-expressing constructs.
In conclusion, we produced two mouse lines that
constitute novel useful tools for studying normal
function of a-synuclein and its role in pathological
processes.
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